The Journal Of Clinical And Aesthetic Dermatology[JOURNAL]
Sun
200 papers
He Who Wills the End Wills the Means: An Overview of Trusts for Physicians.
Cockerell C, Galambus J
J Clin Aesthet Dermatol · 2025 Feb · PMID 40078860
Even though physicians often have the access and ability to generate significant wealth, many report poor financial literacy and education. They may not fully understand the options available to them for passing on their...
Even though physicians often have the access and ability to generate significant wealth, many report poor financial literacy and education. They may not fully understand the options available to them for passing on their wealth to their next of kin. Options include wills, trusts, or, if one dies without a will, simply following the states intestate succession laws. There are multiple types of trusts that each confer different benefits and drawbacks. Physicians in all stages of their career should be aware of these options and strongly consider working with an estate planning attorney and financial planner.
Investigating Efficacy of Atopic Dermatitis Systemic Therapeutics After Discontinuation Part I: Biologics.
Issa NT, Abdin R, Al-Tariq K … +4 more , Jaalouk D, Kaiser M, Del Rosso J, Kwatra S
J Clin Aesthet Dermatol · 2025 Feb · PMID 40078859
OBJECTIVE: The authors sought to review published literature on the efficacy of biologics as monotherapy for atopic dermatitis (AD) following discontinuation. METHODS: A comprehensive search of PubMed/MEDLINE was conduct...
OBJECTIVE: The authors sought to review published literature on the efficacy of biologics as monotherapy for atopic dermatitis (AD) following discontinuation. METHODS: A comprehensive search of PubMed/MEDLINE was conducted examining drug withdrawal in AD clinical trials where participants were treated with biologics. Trials were included if they exclusively involved participants with AD that reported the maintenance or achievement of Eczema Area and Severity Index (EASI)-75 and Investigator Global Assessment (IGA) scores of 0 or 1 after withdrawal of biologic therapy. Clinical trials involving multidrug regimens, including those investigating concomitant topical therapeutics, were excluded from our analysis. RESULTS: Five clinical trial programs met our inclusion criteria, each investigating a different biologic: dupilumab, tralokinumab, lebrikizumab, amlitelimab, and rocatinlimab. LIMITATIONS: Limitations to this review include a small number of trials that met the inclusion criteria, variations in study design that hinder direct comparisons, and the absence of long-term follow up data. CONCLUSION: The variability in eligibility criteria, treatment durations, and withdrawal periods across trials presents a major challenge in assessing biologics for AD, complicating the comparison of their sustained responses in the absence of head-to-head studies. This heterogeneity, combined with factors such as disease duration and prior use of systemic medications before trial enrollment, hampers the identification of key pathways in AD pathogenesis and impedes efforts to better understand and characterize the disease.
From the Masterclasses in Dermatology 2024 Meeting: Updates in Psoriasis Treatments.
Childs B, Romanelli S, Merola JF … +1 more , Gottlieb AB
J Clin Aesthet Dermatol · 2025 Feb · PMID 40078858
Psoriasis (PsO) is an immune-mediated, chronic inflammatory skin disease that significantly impairs quality of life. Its treatment landscape is rapidly evolving, providing better disease control. Here, we highlight updat...
Psoriasis (PsO) is an immune-mediated, chronic inflammatory skin disease that significantly impairs quality of life. Its treatment landscape is rapidly evolving, providing better disease control. Here, we highlight updates in biologics, obtaining coverage for biologics under Medicare, the PsO-to-psoriatic arthritis (PsA) transition, and orally administered drugs, as presented at the 2024 Masterclass in Dermatology in Puerto Rico. We provide a concise overview of the evolving therapeutic landscape and its impact on personalized care for patients with PsO. The toolkit of biologics is expanding, with agents that target interleukin (IL)-17 and IL-23 pathways addressing symptoms across multiple disease domains. Interchangeable biosimilars reduce financial barriers to access, particularly for tumor necrosis factor (TNF) inhibitors. An IL-36 receptor antibody, spesolimab, demonstrates efficacy in generalized pustular psoriasis. Further, Medicare has expanded coverage of certain biologics, addressing challenges to treating patients of this population. PsA is an important comorbidity that can significantly reduce quality of life. Recent studies suggest that biologic therapies-including TNF inhibitors, as well as anti-IL-17, anti-IL-23, and anti-IL-12/23 agents-protect against arthritis onset in PsO patients. In addition to traditional modes of delivery, novel formulations address widespread preference for orally administered therapies. Deucravacitinib, a tyrosine kinase (TYK) 2 inhibitor, is highly selective, effective, and safe. Additionally, JNJ-77242113, an investigational IL-23 receptor antagonist, constitutes an orally administered, targeted biologic therapy. Together, these developments are shaping the future for patients with PsO. It is our goal to simplify the complexities of emerging treatment options, offering clinicians a concise and useful guide for patient management.
The Efficacy of Complementary and Alternative Medicines in Medical Dermatology: A Comprehensive Review.
Ufomadu P, Gill BJ, Orengo I … +2 more , Rosen T, Shimizu I
J Clin Aesthet Dermatol · 2025 Feb · PMID 40078857
BACKGROUND: In recent years, there has been a widespread patient use of complementary and alternative medicines (CAMs) for dermatological application, despite few RCT-level studies on these supplements. This creates a ba...
BACKGROUND: In recent years, there has been a widespread patient use of complementary and alternative medicines (CAMs) for dermatological application, despite few RCT-level studies on these supplements. This creates a barrier for dermatologists and others in counseling patients who may be using or might be tempted to use these CAM agents. This review investigates various CAM modalities used by patients for medical dermatology, exploring their efficacy and toxicity profiles. METHODS: A comprehensive review was performed on the effectiveness of several CAMs utilized in medical dermatology by patients. A literature search was conducted using PubMed, Embase, Google Scholar, Web of Science, and Cochrane. RESULTS: Most CAM modalities had statistically insignificant results, and for agents that had significant results in efficacy, these studies were questionable with flawed designs and methodologies. CONCLUSION: These CAM supplements have promising potential in dermatologic use and are deserving of further investigation in well-crafted RCT-level studies. A more practical focus in future studies should involve a comparison of CAM agents to conventional therapies either alone or in an integrative fashion. This would accurately represent how these agents will be used clinically by actual patients and will be more helpful to clinicians. In the meantime, dermatologists should be aware of bias in published studies demonstrating the effectiveness of certain CAM modalities, and their corresponding toxicity. By doing so, physicians act as a valuable resource to patients who would like to explore various CAM products, better guiding patient interactions and treatment with improved patient outcomes.
Skin 101: Understanding the Fundamentals of Skin Barrier Physiology-Why is This Important for Clinicians?
Del Rosso JQ, Kircik L
J Clin Aesthet Dermatol · 2025 Feb · PMID 40078856
This article reviews epidermal barrier dysfunctions and more thoroughly discusses the stratum corneum (SC) permeability barrier, physiologic self-repair mechanisms in healthy skin, and the clinical and structural effects...
This article reviews epidermal barrier dysfunctions and more thoroughly discusses the stratum corneum (SC) permeability barrier, physiologic self-repair mechanisms in healthy skin, and the clinical and structural effects of an overstressed SC permeability barrier. Discussion includes epidermal barrier impairments induced by both exogenous exposures and endogenous factors such as specific dermatologic disorders. Due the plethora of skin care products on the market and the variability of their contents and vehicle formulations, this article addresses core concepts required to optimize skin care product selection, including for specific disease states such as atopic dermatitis, psoriasis, acne vulgaris, and rosacea. To summarize, the selection of skin care products is directed at maintaining SC hydration, including assisting the SC in self-repair when conditions are adverse. This approach optimizes the ability to sustain healthy skin structure, function and appearance.
Achievement of Optimal Treatment Targets with Oral Janus Kinase Inhibition in Elderly Patients with Atopic Dermatitis: A Real-world, Multicenter, Retrospective Study.
Dasilva DR, Desir N, Encarnacion IN … +3 more , Issa N, Song EJ, Mollanazar NK
J Clin Aesthet Dermatol · 2025 Feb · PMID 40078855
OBJECTIVE: Oral Janus kinase inhibitors (JAKi) have demonstrated high levels of efficacy with acceptable safety in patients with atopic dermatitis (AD), yet there remains significant hesitancy among the dermatologic comm...
OBJECTIVE: Oral Janus kinase inhibitors (JAKi) have demonstrated high levels of efficacy with acceptable safety in patients with atopic dermatitis (AD), yet there remains significant hesitancy among the dermatologic community to use JAKi in elderly populations due to the potential increased risk of serious adverse events in this population. We aimed to perform a retrospective review to describe real-world outcomes for the use of selective JAK-1 inhibitors in patients with AD aged 65 years or older. METHODS: We conducted a multicenter retrospective review. AD cases were identified by ICD-10-CM codes L20.8/L20.89/L20.9. Patients aged 65 years or older years treated with a selective JAK-1 inhibitor were included. Body surface area (BSA), Investigator Global Assessment (IGA), and Peak Pruritus Numerical Rating Scale (NRS) were collected and evaluated independently. RESULTS: Thirty-eight AD cases in patients aged 65 years or older treated with a selective JAK-1 inhibitor were identified. Patients were aged 65 to 96 years, and treatment duration ranged from 4 to 28 months. Thirty-six out of 38 patients (94.7%) tolerated treatment well; one was switched to another JAKi due to mood lability and another paused therapy during hospitalization for septic pneumonia. Thirty-five out of 37 (94.6%) patients achieved an IGA of 0/1, 28/30 (93.3%) achieved an NRS of 0/1, and 30/30 (100%) had a peak pruritus response with improvement of ≥4 points on NRS. There were no clinically meaningful laboratory abnormalities throughout the treatment course. No laboratory abnormality resulted in treatment discontinuation. LIMITATIONS: Limitations of this retrospective review include selection bias and missing data. CONCLUSION: We demonstrate the ability to achieve optimal treatment targets and safety of selective JAKi-1 inhibitors in elderly patients with AD.
Overburdened and Undertreated: Hidradenitis Suppurativa in Skin of Color.
Sangha AM
J Clin Aesthet Dermatol · 2024 · PMID 39850506
Abstract loading — click title to view on PubMed.
Review of Statistical Considerations and Data Imputation Methodologies in Psoriasis Clinical Trials.
DiRuggiero D, Trickett C, Hippeli L … +3 more , Park SH, Baum-Jones A, Davidson DS
J Clin Aesthet Dermatol · 2024 · PMID 39850505
Numerous clinical trials have established that various biologic and oral small-molecule therapies are efficacious in patients with psoriasis. However, as there are limited head-to-head trials, healthcare providers may co...
Numerous clinical trials have established that various biologic and oral small-molecule therapies are efficacious in patients with psoriasis. However, as there are limited head-to-head trials, healthcare providers may compare results across multiple trials when providing treatment recommendations. Direct comparisons among agents are challenging because psoriasis trials differ in terms of study design, patient population, and data analysis methodologies. Long-term clinical trials present additional challenges because the number of patients enrolled generally declines over time. The missing patient data that might occur, coupled with the specific approach used to substitute or impute that missing data, might introduce bias and skew efficacy results. In this review, we discuss how variations in study design and analytical methodologies affect efficacy outcomes in clinical trials. We also review published trials of biologic and oral small-molecule therapies for psoriasis to illustrate how issues related to missing data and choices in data imputation methodologies can affect the interpretation of efficacy outcomes. Imputation methodologies discussed include nonresponder imputation, modified nonresponder imputation, treatment failure rules, last observation carried forward, modified baseline observation carried forward, and multiple imputation. This review provides a foundation for the healthcare provider's critical evaluation of the psoriasis literature and emphasizes the importance of considering the level of evidence provided in a clinical trial when making treatment decisions.
Vitiligo Exchange: An Expert Panel Discussion of Two Clinical Cases.
Del Rosso J, Hamzavi I, Grimes P
J Clin Aesthet Dermatol · 2024 Dec · PMID 39830989
This article is based on a roundtable discussion in which three panelists review clinically relevant insights about vitiligo and discuss two cases that illustrate the multiple challenges faced by both patients and clinic...
This article is based on a roundtable discussion in which three panelists review clinically relevant insights about vitiligo and discuss two cases that illustrate the multiple challenges faced by both patients and clinicians in managing this complex disease. The first is a 32-year-old White female patient with Fitzpatrick Skin Type III/IV with extensive depigmentation in the trunk area. The patient achieved 90-percent repigmentation with a combination therapy approach. Treatment included systemic corticosteroids, oral antioxidants, narrowband ultraviolet B phototherapy, and topical therapy initially with tacrolimus ointment followed by topical ruxolitinib cream. Patient counseling around variable rates of progressive repigmentation over time, the significance of combining therapeutic approaches, and the importance of treatment consistency are discussed. The second case is that of a White pediatric female patient with vitiligo, who was treated from the ages of 5 to 11 years, with a break in treatment due to the patient's desire to discontinue treatment. Once treatment recommenced, the patient ultimately achieved 75-percent repigmentation within six months using a combination of narrowband ultraviolet B phototherapy, topical corticosteroids, and topical calcineurin inhibitors. The emotional burden of pediatric vitiligo for patients and their caregivers are discussed, along with joint decision making with this patient and her parents. This was followed by a discussion of the significance of the patient's anti-nuclear antibody positivity and how this affects treatment approach in patients with vitiligo.
Videoconferencing Dysmorphia: The Impact on Self-perception and Desire for Cosmetic Procedures.
Patel PM, Szeto MD, O'Connor K … +4 more , De La Garza H, Kennedy KF, Maymone MBC, Vashi NA
J Clin Aesthet Dermatol · 2025 Jan · PMID 39830830
OBJECTIVE: The authors sought to examine the association between the increased use of videoconferencing and image-enhancing software filters during the COVID-19 pandemic and the corresponding rise in interest in cosmetic...
OBJECTIVE: The authors sought to examine the association between the increased use of videoconferencing and image-enhancing software filters during the COVID-19 pandemic and the corresponding rise in interest in cosmetic procedures. We aimed to discern if heightened exposure to one's digital self-image correlates with a greater inclination toward cosmetic interventions. METHODS: In this cross-sectional questionnaire survey study, adult participants living in the United States were recruited on Amazon's Mechanical Turk platform. Self-reported demographic data, videoconferencing usage, related behaviors, and attitudes concerning cosmetic procedures were assessed. Questionnaire prompts allowed participants to express in a Likert scale format their levels of agreement with certain statements. Frequencies and proportions of responses to each questionnaire item were collected, categorized, and recoded for comparison and analysis. Chi-squared tests were performed to examine associations between questionnaire responses and demographic characteristics, while significant predictors of videoconferencing and image-enhancing filter options were explored via multivariable logistic regression models. RESULTS: The majority of study participants (n=505, 505/545 = 92.7% completion rate) were 18 to 39 years old (80.1%), female (68.1%), and non-White (58.2%). Income levels varied, and 89.2 percent had completed college or graduate school. Videoconferencing was frequent, with 88.6 percent using it more than three days a week, and 68.1 percent using ";touch-up my appearance"; filters more than half the time. Videoconferencing influenced the desire for cosmetic procedures in 55.9 percent of participants, and 57.8 percent were influenced by filter use. Frequent self-viewing was reported by 67 percent, strongly associated with interest in cosmetic procedures. Significant predictors of filter use included higher income (OR 2.436, <0.001) and frequent self-viewing behavior (OR 5.034, <0.001). Notably, mask-wearing was associated with increased self-esteem (68.8%) and reduced desire for cosmetic procedures (67.4%) in frequent self-viewers. LIMITATIONS: Recall bias and the demographic composition of the study participant population may limit the generalizability of these self-reported responses. CONCLUSION: The data reflect the emergence of what may be termed 'videoconferencing dysmorphia,' indicating a significant association between videoconferencing, the application of filters, and the heightened interest in cosmetic procedures among users. This study suggests that digital self-viewing behavior instigates a distinct self-awareness that may drive individuals toward considering cosmetic interventions. These insights are vital for dermatologists in understanding patient motivations, managing expectations, and fostering realistic treatment outcomes.
A Topical Formulation Containing Ferment for Managing Barrier Damage After Mild-Moderate Skin Disruption from Cosmetic Dermatologic Procedures.
Santhanam U, Emmetsberger J, Nole G … +3 more , Ortiz A, Gold M, Saliou C
J Clin Aesthet Dermatol · 2025 Jan · PMID 39830829
OBJECTIVE: The primary objective of these studies was to evaluate the potential of a serum containing Macrocystis pyrifera ferment (MPF-Serum) to both strengthen the barrier of intact skin and enhance barrier recovery af...
OBJECTIVE: The primary objective of these studies was to evaluate the potential of a serum containing Macrocystis pyrifera ferment (MPF-Serum) to both strengthen the barrier of intact skin and enhance barrier recovery after a non-ablative laser procedure or glycolic acid chemical peel. METHODS: Two whole-face clinical trials and three split-face, randomized, controlled clinical trials were conducted in women aged 31 to 65 years. The effect of MPF-Serum on barrier integrity and strength was assessed by transepidermal water loss measurement before and after controlled tape-stripping experiments and in-clinic 70% glycolic acid peel and non-ablative laser procedures. RESULTS: Application of MPF-Serum twice daily for eight weeks on intact skin significantly increased mean moisturization by 16 percent and improved barrier integrity by 11 percent (≤0.05 for both). Likewise, barrier strength across 8x tape-stripped skin showed a 30-percent improvement after eight weeks of treatment. In studies involving non-ablative laser procedures, MPF-Serum pre-treatment or post-treatment improved post-procedure barrier recovery to a greater extent than standard moisturizer. Likewise, in a study involving 70% glycolic peel, MPF-Serum pre-treatment improved post-procedure barrier recovery to a greater extent than no pre-treatment. LIMITATIONS: These clinical studies were conducted at a limited number of sites, with limited sample sizes and populations. CONCLUSION: This topical MPF-Serum effectively improves barrier integrity and strength and helps to reduce recovery time from dermatologic procedures such as glycolic acid peel and laser treatments.
Topical Carboxytherapy for Skin Rejuvenation.
Shamban A, Roberts WE, Bucay V … +3 more , Chilukuri S, Simmons-O'Brien E, Orlinsky D
J Clin Aesthet Dermatol · 2025 Jan · PMID 39830828
Driven by public demand, new safe and effective approaches for achieving dermal rejuvenation are continuously being developed. Recently, there has been growing interest and advances in carbon dioxide therapy, or carboxyt...
Driven by public demand, new safe and effective approaches for achieving dermal rejuvenation are continuously being developed. Recently, there has been growing interest and advances in carbon dioxide therapy, or carboxytherapy. Based on the Bohr effect, carboxytherapy enhances the release of O from the blood into the surrounding tissues in response to increased blood CO. Injections of CO promote wound healing, reduced scar tissue, and increase collagen turnover, making it a useful tool for achieving a broad range of aesthetic benefits. A significant advancement in CO technology is the development of a topical gel for the transcutaneous release of carbon dioxide (CO Lift. Lumisque, Inc., Weston FL). Similar to the changes observed following CO injections, the application CO gel increases microcirculation and capillary growth. For example, applying a CO gel mask after skin rejuvenation procedures, such as nanofractional radiofrequency therapy, is a safe and effective means to improve clinical outcomes and reduce treatment-related adverse events. The following manuscript is a review and discussion based on a roundtable discussion conducted at the Generational Dermatology Symposium in Rancho Mirage, California, on February 16-19, 2023. The use of carboxytherapy using a CO gel represents a new multi-purpose new for medical, aesthetic, pediatric, and female health practitioners for improving patient skin health and appearance.
Utilization of Internet and Social Media by Outpatient Dermatology Patients: A Prospective, Cross-sectional Study.
Saizan AL, Montgomery SN, Ding L … +2 more , Hurtado ACM, Elbuluk N
J Clin Aesthet Dermatol · 2025 Jan · PMID 39830827
BACKGROUND: Online health-related information (HRI) has expanded access to medical knowledge. While there are benefits to the increasing availability of online HRI, there may be limitations to the accuracy, quality of in...
BACKGROUND: Online health-related information (HRI) has expanded access to medical knowledge. While there are benefits to the increasing availability of online HRI, there may be limitations to the accuracy, quality of information, and utilization across patient demographics. METHODS: A survey was administered to dermatology outpatients at the Keck School of Medicine of the University of Southern California to examine the utilization of internet and social media for acquiring dermatology-related information (DRI). RESULTS: A total of 200 patients completed the survey. A majority (90%) indicated utilizing the internet to research information about their dermatological condition. Approximately 74 percent researched their dermatological condition before visiting the dermatologist, and 80 percent researched their condition after seeing a dermatologist. Younger patients (ages 18-25) were more likely to utilize online HRI before and after their visit. When stratified by income level, those with an income of less than $20,000 a year were more likely to search online for symptom management. Overwhelmingly, patients (99%) preferred to receive DRI from a dermatologist over internet or social media. LIMITATIONS: A limitation of our study is the exclusion of individuals with dermatologic issues who do not seek in-person dermatologic care, which may contribute to selection bias. CONCLUSION: There are differences across demographics in the utilization of the internet and social media for obtaining DRI. Understanding patients' interactions with online HRI may allow providers and patients to work synergistically, leveraging online resources to support the dissemination of credible information and optimize patient outcomes.
Recalcitrant Pediatric Facial Vitiligo Successfully Treated with Roflumilast Cream 0.3% Once Daily.
Warren K, Sanchez S
J Clin Aesthet Dermatol · 2025 Jan · PMID 39830826
Vitiligo is an autoimmune disorder that causes melanocyte damage and pigment loss. The clinical presentation of vitiligo consists of patchy areas of lighter skin and results from a loss of functioning melanocytes and may...
Vitiligo is an autoimmune disorder that causes melanocyte damage and pigment loss. The clinical presentation of vitiligo consists of patchy areas of lighter skin and results from a loss of functioning melanocytes and may be more visible in darker skin toned patients. Vitiligo affects approximately 2 percent of children and adolescents in the United States, with half of the affected cases undiagnosed. Pediatric patients are at a high risk of experiencing psychosocial adverse events such as depression and anxiety if the vitiligo is not quickly or effectively treated due primarily to the visual presentation of the disease. These adverse events may be seen especially in patients with a darker skin tone. Treatments for pediatric vitiligo in the past has usually included phototherapy, topical corticosteroids, vitamin D and calcineurin inhibitors; topical ruxolitinib has been approved more recently for nonsegmental vitiligo in patients 12 years of age and older. In cases where disease is recalcitrant, the need for additional therapies is warranted. Roflumilast cream 0.3% is a highly selective, non-steroidal and potent topical phosphodiesterase 4 inhibitor approved in 2022 by the United States Food and Drug Administration for the treatment of psoriasis, in 2023 as a foam for the treatment of seborrheic dermatitis and in 2024, roflumilast cream 0.15% was approved for the treatment of atopic dermatitis, including in children down to six years of age. Topical roflumilast is well tolerated with a favorable safety profile among pediatric dermatology populations. We describe four cases of pediatric skin of color patients with facial vitiligo that were refractory to topical corticosteroids, ruxolitinib and phototherapy. All patients were started on roflumilast cream 0.3% once daily and demonstrated improvement in repigmentation.
Botulinum Toxin-loaded Detachable Dissolvable Microneedles for Primary Axillary Hyperhidrosis: A Pilot Study on Efficacy and Safety.
Triwatcharikorn J, Charoenchaipiyakul K, Sansureerungsikul T … +10 more , Chuenboonngarm N, Kantikosum K, Chottawornsak N, Chancheewa B, Puaratanaarunkon T, Panchaprateep R, Kumtornrut C, Pukfukdee P, Wanichwecharungruang S, Asawanonda P
J Clin Aesthet Dermatol · 2025 Jan · PMID 39830825
OBJECTIVE: Botulinum toxin injection is a well-established treatment for primary hyperhidrosis. The botulinum toxin-loaded detachable dissolvable microneedles (BoNT-MNs) were developed in a result of disadvantages of the...
OBJECTIVE: Botulinum toxin injection is a well-established treatment for primary hyperhidrosis. The botulinum toxin-loaded detachable dissolvable microneedles (BoNT-MNs) were developed in a result of disadvantages of the intradermal procedure. This pilot study aims to evaluate the efficacy and safety of BoNT-MNs. METHODS: This within-subject study included ten adults (N=10; 100% female) with mild primary axillary hyperhidrosis. BoNT-MNs patches were prepared and each microneedle patch contained 15 units of onabotulinum toxin. BoNT-MNs and placebo patches were randomly applied to different sides of axilla. Iodine-starch test, dermatologists' and patients' satisfaction scores were assessed at baseline and Weeks 1, 2, 3, 4, 8, 12, 16, 20, and 24. RESULTS: All ten female subjects completed the trial. Notably, on the BoNT-MNs side, iodine starch scores exhibited an onset at Week 2, with a 57.14-percent reduction at Week 12, returning to baseline after Week 20. Dermatologists' and patients' satisfaction scores were consistently superior to the placebo side from Week 2 and Week 1, respectively, until Week 16, with statistical significance (<0.05) observed at Week 12 and Week 2. LIMITATIONS: This study involved a limited number of female participants and administered a single, small dosage of botulinum toxin in the BoNT-MNs. CONCLUSIONS: Botulinum toxin-loaded detachable dissolvable microneedles patches offer a safe and effective method for reducing axillary sweating. CLINICAL TRIAL: This study was approved by the Institutional Review Board of Faculty of Medicine, Chulalongkorn University with IRB number 567/63, and registered in the Thai Clinical Trials Registry (Thaiclinicaltrials.org) under registration number TCTR20201230002.
Real-World Use of Tapinarof Cream 1% Once Daily in Patients with Seborrheic Dermatitis: A Case Series.
Issa NT, Pomaville L
J Clin Aesthet Dermatol · 2025 Jan · PMID 39830824
Seborrheic dermatitis (SD) is an inflammatory skin disease with multifactorial etiology, involving genetic and environmental factors. Many conventional therapies for SD (ie, topical antifungals, topical corticosteroids)...
Seborrheic dermatitis (SD) is an inflammatory skin disease with multifactorial etiology, involving genetic and environmental factors. Many conventional therapies for SD (ie, topical antifungals, topical corticosteroids) are associated with incomplete efficacy, frequent and sometimes rapid disease recurrence, and restrictions on duration of therapy and anatomic sites of application. This may be because they cannot target multiple disease processes and/or are limited by safety considerations. Topical roflumilast foam was approved for the treatment of SD in 2023, but additional options are needed. The pathophysiology of atopic dermatitis (AD) and psoriasis have similarities with SD, supporting the hypothesis that tapinarof cream 1% once daily (QD) may be beneficial and well tolerated for patients with SD. Tapinarof is a non-steroidal, topical aryl hydrocarbon receptor agonist approved for the treatment of plaque psoriasis in adults. Tapinarof downregulates pro-inflammatory cytokines implicated in AD and plaque psoriasis, restores the skin barrier through upregulation of skin barrier components, and reduces oxidative stress. Here, we report that tapinarof cream 1% QD used for the treatment of four adults with mild-to-severe SD affecting the face, neck, back, and chest, demonstrated a rapid onset of efficacy and noticeable improvements in disease activity. Efficacy was maintained after treatment discontinuation, indicating a possible remittive effect as previously described in plaque psoriasis. The efficacy and potential remittive effect may be attributed to the unique mechanism of action and clinical profile of tapinarof cream. Tapinarof is a novel topical therapy that may be beneficial for patients with SD.
Topical Brimonidine Tartrate 0.33% Gel versus 577-nm Pro-yellow Laser for the Treatment of Post-acne Erythema: A Comparative Study.
Mohamed EA, Obaid ZM, Fouda I
J Clin Aesthet Dermatol · 2025 Jan · PMID 39830823
BACKGROUND: Post acne erythema (PAE) is a common sequela of inflammatory acne vulgaris resulting from the dilatation of microcapillaries within the papillary dermis, thinning of the epidermis, and release of inflammatory...
BACKGROUND: Post acne erythema (PAE) is a common sequela of inflammatory acne vulgaris resulting from the dilatation of microcapillaries within the papillary dermis, thinning of the epidermis, and release of inflammatory cytokines. The authors sought to compare the safety and efficacy of topical Brimonidine tartrate 0.33% gel versus A 577-nm pro-yellow laser for treatment of post acne erythema. METHODS: This was a comparative study, randomized clinical trials conducted on 60 adult patients with PAE. Patients were assigned into two groups: Group I included 30 patients who received brimonidine tartrate 0.33% gel once daily for three months, and Group II included 30 patients who received Pro-yellow laser with 577-nm therapy, for four sessions at three weeks intervals. Evaluation of erythema was done by Clinician's Erythema Assessment (CEA) and Patient's Self-Assessment (PSA) scales at baseline and at the end of the therapy. The dermoscopic images were analyzed for percent area of erythema and the optical density (OD) using ImageJ® freeware. RESULTS: Twenty-two patients (73.3%) were females and eight patients (26.7%) were males in Group I. In Group II, 20 patients (66.7%) were females and 10 patients (33.3%) were males. The mean±SD age of the studied groups was 22.07 years ±2.64 ranging from 20 to 24 years in Group I versus 20.93 years ±2.88 ranging from 19 to 23 years in Group II. Clinical improvement is distributed as follows among Group I; 56.7 percent are excellent, 56.7 percent good, 26.7 percent poor, and 10 percent fair for Group II; 33.3 percent good, 6.7 percent poor, and 60 percent excellent. There was no statistically significant difference between studied groups as regard Clinician's Erythema Assessment (CEA), Patient's Self-Assessment (PSA) mean area percentage and the optical density (OD) before treatment, while a statistically significant difference between studied groups after treatment was observed (<0.001). CONCLUSION: Topical brimonidine tartrate 0.33% gel and 577-nm pro yellow laser were effective and well tolerated therapeutic options for treatment of Post acne erythema (PAE), however the 577-nm Pro yellow laser was superior to brimonidine tartrate 0.33% gel.
Trending Psychiatric Comorbidities in Patients with Alopecia Areata in the United States from 2002 to 2019.
Peterson H, Miao KL, Huang MY … +1 more , Armstrong AW
J Clin Aesthet Dermatol · 2025 Jan · PMID 39830822
Abstract loading — click title to view on PubMed.
Prospective Pilot Evaluation of the Safety, Tolerability, and Efficacy of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel plus Clascoterone 1% Cream in Adult Patients with Acne.
Yu Z, Swenson K, Graber E
J Clin Aesthet Dermatol · 2025 Jan · PMID 39830821
BACKGROUND: Acne vulgaris (acne) is a common disorder with a complex, multi-faceted pathophysiology. To date, there has not been a single topical treatment that targets all aspects of acne pathophysiology (ie, increased...
BACKGROUND: Acne vulgaris (acne) is a common disorder with a complex, multi-faceted pathophysiology. To date, there has not been a single topical treatment that targets all aspects of acne pathophysiology (ie, increased sebum production, presence of , inflammation, and follicular hyperkeratinization). As such, topical treatments need to be utilized in combination to target all four of the major recognized pathophysiologic components in acne lesion formation. OBJECTIVE: This single-center prospective evaluation assessed the safety, tolerability, and efficacy of clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide (BPO) 3.1% gel used concurrently with clascoterone 1% cream for treatment of acne in an eight-week, open-label pilot evaluation. METHODS: Six subjects (N=6), aged 21 to 27, were enrolled and evaluated at Week 0, Week 2, Week 4, and Week 8 with respect to erythema, dryness, and inflammatory lesion count (ILC). RESULTS: ILC decreased from 23.50 +/- 8.17 at baseline to 9.50 +/- 7.53 at Week 8 from baseline to Week 12. Average subject-reported adherence rate was 93.81%, and the most commonly reported side effects were burning/stinging and erythema; all were rated as mild. CONCLUSION: This pilot evaluation, albeit small and open-label, demonstrates promising results for the first studied combination of topical agents to target all four aspects of acne pathophysiology. Further large-scale studies are needed to further elucidate the additive efficacy and side effect profile when these two topical medications are used concomitantly.
Don't Let Beauty Blind You: Unveiling Clinical Diagnoses During Cosmetic Dermatology Practice.
Aristizabal MA, Soto T, Tolaymat L … +1 more , Bruce AJ
J Clin Aesthet Dermatol · 2024 · PMID 39759903
There has been a notable rise in the prevalence of cosmetic dermatology services worldwide, involving a diverse range of providers. Patients presenting with cosmetic concerns should be thoroughly assessed and require met...
There has been a notable rise in the prevalence of cosmetic dermatology services worldwide, involving a diverse range of providers. Patients presenting with cosmetic concerns should be thoroughly assessed and require meticulous attention because subtle, unexpected clinical cues might necessitate the application of dermatologic expertise. In this study, we present a case series involving patients who sought cosmetic care at an academic cosmetic dermatology center, revealing subsequent diagnoses of significant medical conditions. This underscores the critical importance of comprehensive training and substantial clinical exposure for practitioners in the highly nuanced field of dermatology.
About
- Frequency
- Sun
- Papers found
- 200
- RSS feed
- Subscribe